ClinicalTrials.gg
CompletedNCT05542953Updated Sep 8, 2025

[18F]APN-1607 PET in Subjects With AD Compared to HC

A Phase 3 interventional study of [18F]APN-1607 in Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease and Healthy Volunteers, sponsored by APRINOIA Therapeutics. Completed at 1 site in China. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by APRINOIA Therapeutics · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Non-randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Enrollment
49th of 176
230 · median 100
Started
2022
with 22 others
Phase 3
33 of 260
15 open now
Registered
85th of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 49th largest by enrollment of the 176 interventional ones that give a count, is one of 23 that started in 2022, is one of 33 in phase 3, and was the 85th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MCI, subjects with AD dementia, and healthy subjects.

03

Conditions studied

  • Alzheimer's Disease
  • Mild Cognitive Impairment Due to Alzheimer's Disease
  • Healthy Volunteers

Browse trials for

Keywords

  • AD
  • MCI
  • HV
  • APN-1607
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria for All Subjects:

  • Written must be obtained before any assessment is performed.
  • Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or for at least 1 year (ie, 12 consecutive months with no menses without an alternative medical cause) or, if they are of , must commit to use a barrier method or to abstinence for the duration of the study and must have negative serum and urine pregnancy tests.
  • Male subjects and their partners of childbearing potential must commit to the use of two methods of contraception, one of which is a barrier method (ie, condom), or to abstinence for the study duration.
  • Male subjects must not donate sperm for the study duration.
  • Willing and able to participate in all study procedures.

Inclusion Criteria for Healthy Subjects:

  • Medically healthy with no finding on physical examination, laboratory profiles, VS, or at screening and upon reporting for the [18F]APN-1607 Imaging Visit.
  • No cognitive impairment based on neuropsychological battery and as judged by the Investigator.
  • No first-degree family history of early-onset AD or other neurological disease associated with dementia (prior to age 65).

Inclusion Criteria for Subjects with MCI:

  • Written informed consent must be obtained before any assessment is performed.
  • Must meet all of the clinical criteria for MCI according to NIA-AA criteria, including lack of functional impairment sufficient to warrant a diagnosis of dementia.

Inclusion Criteria for Subjects with AD:

  • Has a diagnosis of AD dementia according to NIA-AA criteria, including significant impairment of activities of daily living.
  • Medications taken for symptomatic treatment of AD must have been stable for 30 days prior to screening and through completion of the neuropsychological battery.

Exclusion Criteria:

Exclusion Criteria for All Subjects:

  • Current or prior history (within the last 10 years) of alcohol or drug abuse.
  • Known to [18F]APN-1607 or its .
  • Clinically significant active or unstable medical illness or planned surgical procedures during the study period. History of cancer (other than nonmelanoma skin cancers or stable, local prostate cancer), unless without evidence of active disease within the last 3 years and without ongoing medical or surgical therapy.
  • Laboratory tests with clinically significant abnormalities or a history or evidence of clinically significant unstable medical illness.
  • Prior participation in other research protocols or clinical care in the last year in addition to the radiation exposure expected from participation in this clinical study, such that radiation exposure exceeds local guidelines.
  • Pregnant, lactating or breastfeeding.
  • Unsuitable veins for repeated venipuncture.
  • Implants, or history of claustrophobia in MRI.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    Alzheimer's Disease

    AD subjects will undergo PET imaging using \[18F\]APN-1607.

    Drug: [18F]APN-1607

  • Experimental
    Mild Cognitive Impairment Due to Alzheimer's Disease

    MCI subjects will undergo PET imaging using \[18F\]APN-1607.

    Drug: [18F]APN-1607

  • Experimental
    Healthy Volunteers

    Healthy control subjects will undergo PET imaging using \[18F\]APN-1607.

    Drug: [18F]APN-1607

Interventions

  • In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.

06

What researchers measure

Primary outcomes

  1. Assessment of [18F]APN-1607 Uptake Patterns by Regional SUVR Values

    Regional \[18F\]APN-1607 uptake patterns will be assessed in regions of interest (ROIs) and an iROI that are relevant to AD pathology. \[18F\]APN-1607 uptake patterns identified by regional analysis will be compared among healthy subjects, subjects with MDAD, and subjects with AD dementia. Standard uptake value (SUV) will be calculated for each ROI, and SUVRs will be calculated by normalizing SUV of ROIs to the SUV of relevant reference region.

    Time frame: 15 months

Secondary outcomes

  1. Safety and Tolerability Profile Measured by Adverse Events (AEs)

    Safety and tolerability profile for the administration of \[18F\]APN-1607 and positron emission tomography (PET) scanning are measured by number of participants with adverse events (AEs).

    Time frame: 15 months

07

Study locations

1 site
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Dec 2023, 23 months.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 23 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2022
First posted
Sep 16, 2022
StartActual
Jan 21, 2022
Primary completionActual
Dec 25, 2023
CompletionActual
Dec 25, 2023
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05542953
Lead sponsor
APRINOIA Therapeutics
Responsible party
Sponsor
First posted
Sep 16, 2022
Start date
Jan 21, 2022
Primary completion
Dec 25, 2023
Completion
Dec 25, 2023
Last update
Sep 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florzolotau F-18

Start the discussion